EcoDrugPlus

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPNAG00000009065
Gene Symbol: ARAF
3 Cross references
190 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPNAG00000014319
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSPNAG00000023254
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSPNAG00000017353
Gene Symbol: ADAM17
3 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSPNAG00000010236
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSPNAG00000024901
Gene Symbol: AKT1
4 Cross references
192 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSPNAG00000003657
Gene Symbol: AKT1
3 Cross references
132 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSPNAG00000012895
Gene Symbol: AKT2
3 Cross references
210 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSPNAG00000013431
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSPNAG00000006867
Gene Symbol: ABCC8
3 Cross references
228 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSPNAG00000030045
Gene Symbol: ABCC8
3 Cross references
166 Possible Orthologues:

Atp-Binding Cassette Sub-Family C Member 9-Like

Ensembl ID : ENSPNAG00000003774
Gene Symbol: LOC108439416
3 Cross references
234 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).